Statins and coronary artery bypass graft surgery: Preoperative and postoperative efficacy and safety

Expert Opinion on Drug Safety

Volumn 8, Issue 5, 2009, Pages 559-571

  Kulik, Alexander ^a   Ruel, Marc ^b  

^a ARIZONA HEART INSTITUTE   (United States)

^b UNIVERSITY OF OTTAWA HEART INSTITUTE   (Canada)

Author keywords

Coronary artery bypass graft surgery; Coronary artery disease; Efficacy; Lipids; Safety; Saphenous vein graft disease; Statins

Indexed keywords

ATORVASTATIN; COLESTIPOL; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; MEVINOLIN; NICOTINIC ACID; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

CARDIOPULMONARY BYPASS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; DISEASE COURSE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; HEART ATRIUM FIBRILLATION; HEART MUSCLE REVASCULARIZATION; HUMAN; HYPERCHOLESTEROLEMIA; KIDNEY DYSFUNCTION; LIVER TOXICITY; LONG TERM CARE; LOW DRUG DOSE; MYALGIA; MYOPATHY; NEUROLOGIC DISEASE; POSTOPERATIVE CARE; PRACTICE GUIDELINE; PREOPERATIVE CARE; RECURRENT DISEASE; REVIEW; RHABDOMYOLYSIS; RISK BENEFIT ANALYSIS; SIDE EFFECT; STROKE; SYSTEMATIC REVIEW; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; VEIN GRAFT DISEASE;

ANIMALS; CARDIOVASCULAR DISEASES; CHOLESTEROL, LDL; COGNITION DISORDERS; CORONARY ARTERY BYPASS; CORONARY RESTENOSIS; DRUG UTILIZATION; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; KIDNEY FAILURE, ACUTE; MALE; META-ANALYSIS AS TOPIC; POSTOPERATIVE CARE; POSTOPERATIVE COMPLICATIONS; PRACTICE GUIDELINES AS TOPIC; PREOPERATIVE CARE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETROSPECTIVE STUDIES; RHABDOMYOLYSIS; TREATMENT OUTCOME;

EID: 69449086548     PISSN: 14740338     EISSN: None     Source Type: Journal    
DOI: 10.1517/14740330903188413     Document Type: Review

References (127)

1. Fitzgibbon GM, Kafka HP, Leach AJ, et al. Coronary bypass graft fate and patient outcome: angiographic follow-up of 5,065 grafts related to survival and reoperation in 1,388 patients during 25 years. J Am Coll Cardiol 1996;28:616-626 (Pubitemid 26288642)
2. Motwani JG, Topol EJ. Aortocoronary saphenous vein graft disease: pathogenesis, predisposition, and prevention. Circulation 1998;97:916-931 (Pubitemid 28113931)
3. Campeau L, Enjalbert M, Lesperance J, et al. The relation of risk factors to the development of atherosclerosis in saphenous-vein bypass grafts and the progression of disease in the native circulation. A study 10 years after aortocoronary bypass surgery. N Engl J Med 1984;311:1329-1332 (Pubitemid 15129601)
4. Daida H, Yokoi H, Miyano H, et al. Relation of saphenous vein graft obstruction to serum cholesterol levels. J Am Coll Cardiol 1995;25:193-197
5. Endo A, Kuroda M, Tanzawa K. Competitive inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase by ML-236A and ML-236B fungal metabolites, having hypocholesterolemic activity. FEBS Lett 1976;72:323-326 •• This landmark paper documented HMG-CoA inhibition for the first time using fungal metabolites. (Pubitemid 8017240)
6. Grundy SM. HMG-CoA reductase inhibitors for treatment of hypercholesterolemia. N Engl J Med 1988;319:24-33 (Pubitemid 18163969)
7. Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature 1990;343:425-430
8. Tobert JA. Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors. Nat Rev Drug Discov 2003;2:517-526 (Pubitemid 37361744)
9. Brown MS, Goldstein JL. Multivalent feedback regulation of HMG CoA reductase, a control mechanism coordinating isoprenoid synthesis and cell growth. J Lipid Res 1980;21:505-517
10. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366:1267-1278 •• This meta-analysis summarizing 14 randomized controlled trials confirmed the efficacy and safety of statin therapy in patients with atherosclerotic disease.
11. Rossouw JE. Lipid-lowering interventions in angiographic trials. Am J Cardiol 1995;76:86C-92C
12. Calabro P, Yeh ET. The pleiotropic effects of statins. Curr Opin Cardiol 2005;20:541-546
13. Black DM. A general assessment of the safety of HMG CoA reductase inhibitors (statins). Curr Atheroscler Rep 2002;4:34-41
14. Armitage J. The safety of statins in clinical practice. Lancet 2007;370:1781-1790
15. Davignon J. Beneficial cardiovascular pleiotropic effects of statins. Circulation 2004;109:III39-43 (Pubitemid 38786442)
16. Lazar HL. Role of statin therapy in the coronary bypass patient. Ann Thorac Surg 2004;78:730-740 (Pubitemid 38980821)
17. McFarlane SI, Muniyappa R, Francisco R, et al. Clinical review 145: pleiotropic effects of statins: lipid reduction and beyond. J Clin Endocrinol Metab 2002;87:1451-1458 (Pubitemid 34615220)
18. Werba JP, Tremoli E, Massironi P, et al. Statins in coronary bypass surgery: rationale and clinical use. Ann Thorac Surg 2003;76:2132-2140 (Pubitemid 37510562)
19. Cimino M, Gelosa P, Gianella A, et al. Statins: multiple mechanisms of action in the ischemic brain. Neuroscientist 2007;13:208-213 (Pubitemid 46801757)
20. Merla R, Daher IN, Ye Y, et al. Pretreatment with statins may reduce cardiovascular morbidity and mortality after elective surgery and percutaneous coronary intervention: clinical evidence and possible underlying mechanisms. Am Heart J 2007;154:391-402 (Pubitemid 47071895)
21. Yang Z, Kozai T, van der Loo B, et al. HMG-CoA reductase inhibition improves endothelial cell function and inhibits smooth muscle cell proliferation in human saphenous veins. J Am Coll Cardiol 2000;36:1691-1697 (Pubitemid 30826009)
22. Indolfi C, Cioppa A, Stabile E, et al. Effects of hydroxymethylglutaryl coenzyme A reductase inhibitor simvastatin on smooth muscle cell proliferation in vitro and neointimal formation in vivo after vascular injury. J Am Coll Cardiol 2000;35:214-221 (Pubitemid 30061283)
23. Porter KE, Naik J, Turner NA, et al. Simvastatin inhibits human saphenous vein neointima formation via inhibition of smooth muscle cell proliferation and migration. J Vasc Surg 2002;36:150-157 (Pubitemid 41122904)
24. Kulik A, Levin R, Ruel M, et al. Patterns and predictors of statin use after coronary artery bypass graft surgery. J Thorac Cardiovasc Surg 2007;134:932-938 (Pubitemid 47445596)
25. Serruys PW, Morice MC, Kappetein AP, et al. Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. N Engl J Med 2009;360:961-972
26. Pasternak RC, Smith SC Jr, Bairey-Merz CN, et al. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. Circulation 2002;106:1024-1028 (Pubitemid 34925341)
27. Christenson JT. Preoperative lipid-control with simvastatin reduces the risk of postoperative thrombocytosis and thrombotic complications following CABG. Eur J Cardiothorac Surg 1999;15:394-9; discussion 9-400 • This randomized trial involving 77 patients with hypercholesterolemia reported that perioperative simvastatin reduced myocardial infarction and vein graft disease after CABG.
28. Christenson JT. Preoperative lipid control with simvastatin protects coronary artery bypass grafts from obstructive graft disease. Am J Cardiol 2001;88:896-9, A8
29. Dotani MI, Elnicki DM, Jain AC, et al. Effect of preoperative statin therapy and cardiac outcomes after coronary artery bypass grafting. Am J Cardiol 2000;86:1128-30, A6
30. Pan W, Pintar T, Anton J, et al. Statins are associated with a reduced incidence of perioperative mortality after coronary artery bypass graft surgery. Circulation 2004;110:II45-9 (Pubitemid 39263697)
31. Pascual DA, Arribas JM, Tornel PL, et al. Preoperative statin therapy and troponin T predict early complications of coronary artery surgery. Ann Thorac Surg 2006;81:78-83 (Pubitemid 41815377)
32. Clark LL, Ikonomidis JS, Crawford FA Jr, et al. Preoperative statin treatment is associated with reduced postoperative mortality and morbidity in patients undergoing cardiac surgery: an 8-year retrospective cohort study. J Thorac Cardiovasc Surg 2006;131:679-685
33. Thielmann M, Neuhauser M, Marr A, et al. Lipid-lowering effect of preoperative statin therapy on postoperative major adverse cardiac events after coronary artery bypass surgery. J Thorac Cardiovasc Surg 2007;134:1143-1149 (Pubitemid 47633642)
34. Mannacio VA, Iorio D, De Amicis V, et al. Effect of rosuvastatin pretreatment on myocardial damage after coronary surgery: a randomized trial. J Thorac Cardiovasc Surg 2008;136:1541-1548
35. Ali IS, Buth KJ. Preoperative statin use and in-hospital outcomes following heart surgery in patients with unstable angina. Eur J Cardiothorac Surg 2005;27:1051-1056
36. Powell BD, Bybee KA, Valeti U, et al. Influence of preoperative lipid-lowering therapy on postoperative outcome in patients undergoing coronary artery bypass grafting. Am J Cardiol 2007;99:785-789 (Pubitemid 46371397)
37. Subramaniam K, Koch CG, Bashour A, et al. Preoperative statin intake and morbid events after isolated coronary artery bypass grafting. J Clin Anesth 2008;20:4-11
38. Liakopoulos OJ, Choi YH, Haldenwang PL, et al. Impact of preoperative statin therapy on adverse postoperative outcomes in patients undergoing cardiac surgery: a meta-analysis of over 30 000 patients. Eur Heart J 2008;29:1548-59 •• This meta-analysis involving > 30,000 cardiac surgery patients demonstrated the benefits of preoperative statin therapy.
39. Hindler K, Shaw AD, Samuels J, et al. Improved postoperative outcomes associated with preoperative statin therapy. Anesthesiology 2006;105:1260-72; quiz 89-90 • A meta-analysis of cardiac and vascular surgery studies, this paper reported a mortality benefit of preoperative statin administration. (Pubitemid 44808591)
40. Amarenco P, Labreuche J. Lipid management in the prevention of stroke: review and updated meta-analysis of statins for stroke prevention. Lancet Neurol 2009;8:453-463
41. Mathew JP, Grocott HP, McCurdy JR, et al. Preoperative statin therapy does not reduce cognitive dysfunction after cardiopulmonary bypass. J Cardiothorac Vasc Anesth 2005;19:294-299
42. Katznelson R, Djaiani GN, Borger MA, et al. Preoperative use of statins is associated with reduced early delirium rates after cardiac surgery. Anesthesiology 2009;110:67-73
43. Aboyans V, Labrousse L, Lacroix P, et al. Predictive factors of stroke in patients undergoing coronary bypass grafting: statins are protective. Eur J Cardiothorac Surg 2006;30:300-304 (Pubitemid 44056338)
44. Tabata M, Khalpey Z, Pirundini PA, et al. Renoprotective effect of preoperative statins in coronary artery bypass grafting. Am J Cardiol 2007;100:442-444 (Pubitemid 47094706)
45. Huffmyer JL, Mauermann WJ, Thiele RH, et al. Preoperative statin administration is associated with lower mortality and decreased need for postoperative hemodialysis in patients undergoing coronary artery bypass graft surgery. J Cardiothorac Vasc Anesth 2009;23:468-473
46. Pliquett RU, Cornish KG, Peuler JD, et al. Simvastatin normalizes autonomic neural control in experimental heart failure. Circulation 2003;107:2493-2498
47. Korantzopoulos P, Kountouris E, Kolettis T, et al. Anti-inflammatory and antioxidant actions of statins may favorably affect atrial remodeling in atrial fibrillation. Am J Cardiol 2004;93:1200 (Pubitemid 38521064)
48. Lefer AM, Scalia R, Lefer DJ. Vascular effects of HMG CoA-reductase inhibitors (statins) unrelated to cholesterol lowering: new concepts for cardiovascular disease. Cardiovasc Res 2001;49:281-287 (Pubitemid 32119545)
49. Pound EM, Kang JX, Leaf A. Partitioning of polyunsaturated fatty acids, which prevent cardiac arrhythmias, into phospholipid cell membranes. J Lipid Res 2001;42:346-351 (Pubitemid 32270057)
50. Marin F, Pascual DA, Roldan V, et al. Statins and postoperative risk of atrial fibrillation following coronary artery bypass grafting. Am J Cardiol 2006;97:55-60 (Pubitemid 41828123)
51. Patti G, Chello M, Candura D, et al. Randomized trial of atorvastatin for reduction of postoperative atrial fibrillation in patients undergoing cardiac surgery: results of the ARMYDA-3 (Atorvastatin for Reduction of MYocardial Dysrhythmia After cardiac surgery) study. Circulation 2006;114:1455-1461 (Pubitemid 44526999)
52. Virani SS, Nambi V, Razavi M, et al. Preoperative statin therapy is not associated with a decrease in the incidence of postoperative atrial fibrillation in patients undergoing cardiac surgery. Am Heart J 2008;155:541-546
53. Ozaydin M, Dogan A, Varol E, et al. Statin use before by-pass surgery decreases the incidence and shortens the duration of postoperative atrial fibrillation. Cardiology 2007;107:117-121 (Pubitemid 46272262)
54. Mariscalco G, Lorusso R, Klersy C, et al. Observational study on the beneficial effect of preoperative statins in reducing atrial fibrillation after coronary surgery. Ann Thorac Surg 2007;84:1158-1164 (Pubitemid 47417886)
55. Kourliouros A, De Souza A, Roberts N, et al. Dose-related effect of statins on atrial fibrillation after cardiac surgery. Ann Thorac Surg 2008;85:1515-1520 (Pubitemid 351618357)
56. Song YB, On YK, Kim JH, et al. The effects of atorvastatin on the occurrence of postoperative atrial fibrillation after off-pump coronary artery bypass grafting surgery. Am Heart J 2008;156:373 e9-16
57. Lertsburapa K, White CM, Kluger J, et al. Preoperative statins for the prevention of atrial fibrillation after cardiothoracic surgery. J Thorac Cardiovasc Surg 2008;135:405-411 (Pubitemid 351192943)
58. Thomsen RW, Riis A, Kornum JB, et al. Preadmission use of statins and outcomes after hospitalization with pneumonia: population-based cohort study of 29,900 patients. Arch Intern Med 2008;168:2081-2087
59. Kopterides P, Falagas ME. Statins for sepsis: a critical and updated review. Clin Microbiol Infect 2009;15:325-334
60. Coleman CI, Lucek DM, Hammond J, et al. Preoperative statins and infectious complications following cardiac surgery. Curr Med Res Opin 2007;23:1783-1790 (Pubitemid 47300376)
61. Mohamed R, McAlister FA, Pretorius V, et al. Preoperative statin use and infection after cardiac surgery: a cohort study. Clin Infect Dis 2009;48:e66-72
62. Chello M, Mastroroberto P, Patti G, et al. Simvastatin attenuates leucocyte-endothelial interactions after coronary revascularisation with cardiopulmonary bypass. Heart 2003;89:538-543 (Pubitemid 36520805)
63. Chello M, Patti G, Candura D, et al. Effects of atorvastatin on systemic inflammatory response after coronary bypass surgery. Crit Care Med 2006;34:660-667 (Pubitemid 43308253)
64. Chello M, Anselmi A, Spadaccio C, et al. Simvastatin increases neutrophil apoptosis and reduces inflammatory reaction after coronary surgery. Ann Thorac Surg 2007;83:1374-1380 (Pubitemid 46440750)
65. Chello M, Carassiti M, Agro F, et al. Simvastatin blunts the increase of circulating adhesion molecules after coronary artery bypass surgery with cardiopulmonary bypass. J Cardiothorac Vasc Anesth 2004;18:605-609 (Pubitemid 39369959)
66. Chello M, Goffredo C, Patti G, et al. Effects of atorvastatin on arterial endothelial function in coronary bypass surgery. Eur J Cardiothorac Surg 2005;28:805-810 (Pubitemid 41735253)
67. Brull DJ, Sanders J, Rumley A, et al. Statin therapy and the acute inflammatory response after coronary artery bypass grafting. Am J Cardiol 2001;88:431-433 (Pubitemid 32823311)
68. Liakopoulos OJ, Dorge H, Schmitto JD, et al. Effects of preoperative statin therapy on cytokines after cardiac surgery. Thorac Cardiovasc Surg 2006;54:250-254 (Pubitemid 43937759)
69. Nakamura K, Masuda H, Kariyazono H, et al. Effects of atorvastatin and aspirin combined therapy on inflammatory responses in patients undergoing coronary artery bypass grafting. Cytokine 2006;36:201-210 (Pubitemid 46529472)
70. Dereli Y, Ege E, Kurban S, et al. Pre-operative atorvastatin therapy to decrease the systemic inflammatory response after coronary artery bypass grafting. J Int Med Res 2008;36:1248-1254
71. Berkan O, Katrancioglu N, Ozker E, et al. Reduced P-selectin in hearts pretreated with fluvastatin: a novel benefit for patients undergoing open heart surgery. Thorac Cardiovasc Surg 2009;57:91-95
72. Kogan AD, Orenstein S. Lovastatin-induced acute rhabdomyolysis. Postgrad Med J 1990;66:294-296
73. Rosenberg AD, Neuwirth MG, Kagen LJ, et al. Intraoperative rhabdomyolysis in a patient receiving pravastatin, a 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase inhibitor. Anesth Analg 1995;81:1089-1091
74. Alvarez JM, Rawdanowicz TJ, Goldstein J. Rhadbdomyolysis after coronary artery bypass grafting in a patient receiving simvastatin. J Thorac Cardiovasc Surg 1998;116:654-655 (Pubitemid 28460637)
75. Omar MA, Wilson JP, Cox TS. Rhabdomyolysis and HMG-CoA reductase inhibitors. Ann Pharmacother 2001;35:1096-1107
76. Wilhelmi M, Winterhalter M, Fischer S, et al. Massive postoperative rhabdomyolysis following combined CABG/abdominal aortic replacement: a possible association with HMG-CoA reductase inhibitors. Cardiovasc Drugs Ther 2002;16:471-475 (Pubitemid 36255747)
77. Owczarek J, Jasinska M, Orszulak-Michalak D. Drug-induced myopathies. An overview of the possible mechanisms. Pharmacol Rep 2005;57:23-34
78. Staffa JA, Chang J, Green L. Cerivastatin and reports of fatal rhabdomyolysis. N Engl J Med 2002;346:539-540
79. Schouten O, Kertai MD, Bax JJ, et al. Safety of perioperative statin use in high-risk patients undergoing major vascular surgery. Am J Cardiol 2005;95:658-660 (Pubitemid 40255263)
80. Eagle KA, Guyton RA, Davidoff R, et al. ACC/AHA 2004 guideline update for coronary artery bypass graft surgery: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1999 Guidelines for Coronary Artery Bypass Graft Surgery). Circulation 2004;110:e340-437
81. Blankenhorn DH, Nessim SA, Johnson RL, et al. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA 1987;257:3233-3240 •• This pioneering randomized trial illustrated that reducing cholesterol with colestipol-niacin in post-CABG patients reduced the progression of saphenous vein graft disease.
82. Blankenhorn DH, Alaupovic P, Wickham E, et al. Prediction of angiographic change in native human coronary arteries and aortocoronary bypass grafts. Lipid and nonlipid factors. Circulation 1990;81:470-476
83. Cashin-Hemphill L, Mack WJ, Pogoda JM, et al. Beneficial effects of colestipol-niacin on coronary atherosclerosis. A 4-year follow-up. JAMA 1990;264:3013-3017
84. Frick MH, Syvanne M, Nieminen MS, et al. Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol. Lopid Coronary Angiography Trial (LOCAT) Study Group. Circulation 1997;96:2137-2143 (Pubitemid 27425814)
85. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. The Post Coronary Artery Bypass Graft Trial Investigators. N Engl J Med 1997;336:153-162 •• Aggressive reduction of LDL levels below 100 mg/dl reduced vein graft atherosclerosis and the need for coronary reintervention in this landmark randomized controlled trial.
86. Knatterud GL, Rosenberg Y, Campeau L, et al. Long-term effects on clinical outcomes of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation in the post coronary artery bypass graft trial. Post CABG Investigators. Circulation 2000;102:157-165 (Pubitemid 30451771)
87. White CW, Gobel FL, Campeau L, et al. Effect of an aggressive lipid-lowering strategy on progression of atherosclerosis in the left main coronary artery from patients in the post coronary artery bypass graft trial. Circulation 2001;104:2660-2665 (Pubitemid 33108130)
88. Makuuchi H, Furuse A, Endo M, et al. Effect of pravastatin on progression of coronary atherosclerosis in patients after coronary artery bypass surgery. Circ J 2005;69:636-643
89. Gurbuz AT, Zia AA, Cui H, et al. Predictors of mid-term symptom recurrence, adverse cardiac events and mortality in 591 unselected off-pump coronary artery bypass graft patients. J Card Surg 2006;21:28-34
90. Collard CD, Body SC, Shernan SK, et al. Preoperative statin therapy is associated with reduced cardiac mortality after coronary artery bypass graft surgery. J Thorac Cardiovasc Surg 2006;132:392-400 (Pubitemid 44092868)
91. Kulik A, Brookhart MA, Levin R, et al. Impact of statin use on outcomes after coronary artery bypass graft surgery. Circulation 2008;118:1785-1792
92. Papathanasiou A, Toumpoulis IK, Milionis HJ, et al. Statin therapy is associated with reduced total and cardiovascular mortality after coronary artery bypass grafting surgery. Coron Artery Dis 2008;19:619-625
93. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996;335:1001-1009
94. Flaker GC, Warnica JW, Sacks FM, et al. Pravastatin prevents clinical events in revascularized patients with average cholesterol concentrations. Cholesterol and Recurrent Events CARE Investigators. J Am Coll Cardiol 1999;34:106-112
95. LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005;352:1425-35 • In this randomized trial of acute coronary syndrome patients, atorvastatin 80 mg daily reduced major cardiovascular events compared to atorvastatin 10 mg daily.
96. Shah SJ, Waters DD, Barter P, et al. Intensive lipid-lowering with atorvastatin for secondary prevention in patients after coronary artery bypass surgery. J Am Coll Cardiol 2008;51:1938-1943 • Patients with a history of previous CABG had fewer cardiovascular events when they were treated with atorvastatin 80 mg daily in this sub-group analysis of the TNT trial. (Pubitemid 351636440)
97. Brilakis ES, de Lemos JA, Cannon CP, et al. Outcomes of patients with acute coronary syndrome and previous coronary artery bypass grafting (from the Pravastatin or Atorvastatin Evaluation and Infection Therapy [PROVE IT-TIMI 22] and the Aggrastat to Zocor [A to Z] trials). Am J Cardiol 2008;102:552-558
98. Ucar M, Mjorndal T, Dahlqvist R. HMG-CoA reductase inhibitors and myotoxicity. Drug Saf 2000;22:441-457
99. Thompson PD, Clarkson P, Karas RH. Statin-associated myopathy. JAMA 2003;289:1681-1690
100. Pfeffer MA, Keech A, Sacks FM, et al. Safety and tolerability of pravastatin in long-term clinical trials: Prospective Pravastatin Pooling (PPP) project. Circulation 2002;105:2341-2346 (Pubitemid 34556383)
101. Law M, Rudnicka AR. Statin safety: a systematic review. Am J Cardiol 2006;97:52C-60C
102. Bradford RH, Shear CL, Chremos AN, et al. Expanded Clinical Evaluation of Lovastatin (EXCEL) study results. I. Efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia. Arch Intern Med 1991;151:43-49
103. Newman C, Tsai J, Szarek M, et al. Comparative safety of atorvastatin 80 mg versus 10 mg derived from analysis of 49 completed trials in 14,236 patients. Am J Cardiol 2006;97:61-67 (Pubitemid 41828124)
104. Khanderia U, Townsend KA, Eagle K, et al. Statin initiation following coronary artery bypass grafting: outcome of a hospital discharge protocol. Chest 2005;127:455-463 (Pubitemid 40229303)
105. Laufs U, Wassmann S, Hilgers S, et al. Rapid effects on vascular function after initiation and withdrawal of atorvastatin in healthy, normocholesterolemic men. Am J Cardiol 2001;88:1306-1307 (Pubitemid 33132103)
106. Vecchione C, Brandes RP. Withdrawal of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors elicits oxidative stress and induces endothelial dysfunction in mice. Circ Res 2002;91:173-179 (Pubitemid 34827229)
107. Le Manach Y, Godet G, Coriat P, et al. The impact of postoperative discontinuation or continuation of chronic statin therapy on cardiac outcome after major vascular surgery. Anesth Analg 2007;104:1326-1333, table of contents (Pubitemid 46795280)
108. Heeschen C, Hamm CW, Laufs U, et al. Withdrawal of statins increases event rates in patients with acute coronary syndromes. Circulation 2002;105:1446-1452 (Pubitemid 34263276)
109. Smith SC Jr, Allen J, Blair SN, et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation 2006;113:2363-2372
110. Executive summary of the third report of The National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001;285:2486-2497
111. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004;110:227-239 (Pubitemid 38924592)
112. Pearson TA, Laurora I, Chu H, et al. The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med 2000;160:459-467 (Pubitemid 30112269)
113. Fonarow GC, Gawlinski A, Moughrabi S, et al. Improved treatment of coronary heart disease by implementation of a Cardiac Hospitalization Atherosclerosis Management Program (CHAMP). Am J Cardiol 2001;87:819-822 (Pubitemid 32244197)
114. Muhlestein JB, Horne BD, Bair TL, et al. Usefulness of in-hospital prescription of statin agents after angiographic diagnosis of coronary artery disease in improving continued compliance and reduced mortality. Am J Cardiol 2001;87:257-261
115. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004;350:1495-1504 (Pubitemid 38477774)
116. de Lemos JA, Blazing MA, Wiviott SD, et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA 2004;292:1307-1316
117. Pedersen TR, Faergeman O, Kastelein JJ, et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA 2005;294:2437-2445 (Pubitemid 41627921)
118. Cannon CP, Steinberg BA, Murphy SA, et al. Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. J Am Coll Cardiol 2006;48:438-445 •• This meta-analysis summarizing four randomized controlled trials confirmed that intensive lipid-lowering with high dose statin therapy significantly reduces cardiovascular events compared to moderate dose statin therapy.
119. Newby LK, LaPointe NM, Chen AY, et al. Long-term adherence to evidence-based secondary prevention therapies in coronary artery disease. Circulation 2006;113:203-212 (Pubitemid 43754376)
120. Montague T, Taylor L, Martin S, et al. Can practice patterns and outcomes be successfully altered? Examples from cardiovascular medicine. The Clinical Quality Improvement Network (CQIN) Investigators. Can J Cardiol 1995;11:487-492
121. Okrainec K, Pilote L, Platt R, et al. Use of cardiovascular medical therapy among patients undergoing coronary artery bypass graft surgery: results from the ROSETTA-CABG registry. Can J Cardiol 2006;22:841-847 (Pubitemid 44480037)
122. Siskind A, Johnson M, Qureshi A, et al. The impact of automatic prescriptions on reducing low-density lipoprotein cholesterol levels. Eff Clin Pract 2000;3:240-246
123. Robinson JG, Conroy C, Wickemeyer WJ. A novel telephone-based system for management of secondary prevention to a low-density lipoprotein cholesterol < or = 100 mg/dl. Am J Cardiol 2000;85:305-308 (Pubitemid 30052901)
124. Faulkner MA, Wadibia EC, Lucas BD, et al. Impact of pharmacy counseling on compliance and effectiveness of combination lipid-lowering therapy in patients undergoing coronary artery revascularization: a randomized, controlled trial. Pharmacotherapy 2000;20:410-416
125. Baillargeon JP, Lepage S, Larrivee L, et al. Intensive surveillance and treatment of dyslipidemia in the postinfarct patient: evaluation of a nurse-oriented management approach. Can J Cardiol 2001;17:169-175 (Pubitemid 32279730)
126. Senaratne MP, Griffiths J, Mooney D, et al. Effectiveness of a planned strategy using cardiac rehabilitation nurses for the management of dyslipidemia in patients with coronary artery disease. Am Heart J 2001;142:975-981 (Pubitemid 33131805)
127. Lacy CR, Suh DC, Barone JA, et al. Impact of a targeted intervention on lipid-lowering therapy in patients with coronary artery disease in the hospital setting. Arch Intern Med 2002;162:468-473